Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgery Today
Published in: Surgery Today 10/2016

01-10-2016 | Original Article

The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer

Authors: Naohito Beppu, Hidenori Yoshie, Fumihiko Kimura, Tsukasa Aihara, Hiroshi Doi, Norihiko Kamikonya, Nagahide Matsubara, Naohiro Tomita, Hidenori Yanagi, Naoki Yamanaka

Published in: Surgery Today | Issue 10/2016

Login to get access

Abstract

Purpose

To evaluate the safety and efficacy of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy and surgery in patients with poor-risk locally advanced rectal cancer.

Methods

We enrolled eligible patients with poor-risk rectal cancer defined as T3 lower rectal cancer with mesorectal fascia involvement, T4a or T4b tumors or cases with lateral lymph node swelling. The primary endpoint was a pathological complete response (pCR), and the secondary endpoints were the objective response rate (ORR) and the pathological high response rate (Grade 2 plus 3).

Results

Twenty eligible patients were enrolled. The majority (75.0 %, 15/20) of the patients completed four cycles of induction chemotherapy, and all patients completed the radiotherapy (25 Gy/10 fractions/5 days). The global rate of Grade 3–4 toxicities was 30.0 % (6/20 patients). The ORRs were 85.0 % (17/20) and 95.0 % (19/20) in the patients who underwent R0 and R1 resection, respectively. The pathological high response rate was 70.0 % (14/20) and the pCR was 10.0 % (2/20).

Conclusion

The regimen of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy is safe and is associated with good tumor regression in patients with poor-risk locally advanced rectal cancer.
Literature
1.
Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184–90.CrossRefPubMed
2.
Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, Lupattelli M, et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113:223–9.CrossRefPubMed
3.
Breugom AJ, van Gijn W, Muller EW, Berglund Å, van den Broek CB, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26:696–701.CrossRefPubMed
4.
Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859–65.CrossRefPubMed
5.
Maréchal R, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23:1525–30.CrossRefPubMed
6.
Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30:1620–7.CrossRefPubMed
7.
Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:241–8.CrossRefPubMed
8.
Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614–20.CrossRefPubMedPubMedCentral
9.
Beppu N, Matsubara N, Kakuno A, Doi H, Kamikonya N, Yamanaka N, et al. Feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer. 2015;58:479–487.
10.
11.
Japanese Society for Cancer of the Colon and Rectum: General rules for clinical and pathological studies on cancer of the colon, rectum, and anus. 8th edn. Kanehara Shuppan:Tokyo; 2013.
12.
Beppu N, Matsubara N, Noda M, Yamano T, Kakuno A, Doi H, et al. Pathologic evaluation of the response of mesorectal positive nodes to preoperative chemoradiotherapy in patients with rectal cancer. Surgery. 2015;157:743–51.
13.
Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, et al. Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer. 2008;98:1034–8.CrossRefPubMedPubMedCentral
14.
Adachi T, Hinoi T, Egi H, Shimomura M, Ohdan H. Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery. Surg Today. 2015;45:986–92.CrossRefPubMed
15.
Faria S, Kopek N, Hijal T, Liberman S, Charlebois P, Stein B, et al. Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. Colorectal Dis. 2014;16:66–70.CrossRef
16.
Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg. 2012;99:577–83.CrossRefPubMed
17.
Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009;92:210–4.CrossRefPubMed
18.
Beppu N, Matsubara N, Noda M, Yamano T, Kakuno A, Doi H, et al. Short-course radiotherapy with delayed surgery versus conventional chemoradiotherapy: a comparison of the short- and long-term outcomes in patients with T3 rectal cancer. Surgery. 2015;158:225–35.
19.
Ogawa T, Kukita K, Kimura Y, Mizuguchi T, Hirata K. Clinical feasibility of laparoscopic lateral pelvic lymph node dissection following total mesorectal excision for advanced rectal cancer. Surg Today. 2015;45:310–4.CrossRefPubMed
Metadata
Title
The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer
Authors
Naohito Beppu
Hidenori Yoshie
Fumihiko Kimura
Tsukasa Aihara
Hiroshi Doi
Norihiko Kamikonya
Nagahide Matsubara
Naohiro Tomita
Hidenori Yanagi
Naoki Yamanaka
Publication date
01-10-2016
Publisher
Springer Japan
Published in
Surgery Today / Issue 10/2016
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-015-1284-2

Other articles of this Issue 10/2016

Surgery Today 10/2016 Go to the issue

Original Article

Clinical significance of postoperative recovery of serum albumin levels in patients with esophageal cancer who underwent transthoracic esophagectomy

Original Article

A comparison between fentanyl plus celecoxib therapy and epidural anesthesia for postoperative pain management following laparoscopic gastrectomy

Original Article

Clinicopathological characteristics of young patients with sporadic colorectal cancer

Original Article

18F-Fluorodeoxyglucose positron emission tomography (18F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer

Original Article

Clinical features and management of afferent limb syndrome after ileal pouch-anal anastomosis for ulcerative colitis

Original Article

Therapeutic mammoplasty combining partial mastectomy with nipple-areola grafting for patients with early breast cancer: a case series